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0939-4753/ª 2015 Elsevier B.V. All rights reseAbstract Background and aims: Basal insulin analogues have a reduced risk of hypoglycaemia
compared with NPH insulin, but hypoglycaemia still remains a major impediment to achieving
recommended fasting plasma glucose (FPG) targets in patients with diabetes. Insulin degludec
(IDeg) is a new basal insulin that forms soluble multihexamers after subcutaneous injection re-
sulting in an ultra-long duration of action and stable glucose-lowering effect. The aim of this
analysis was to compare the effect of IDeg on FPG and nocturnal conﬁrmed hypoglycaemia as
compared to insulin glargine (IGlar).
Methods and results: Data were included from seven phase 3a, randomised, open-label, treat-to-
target clinical trials in which once-daily IDeg was compared with once-daily IGlar. Two trials
included a total of 957 patients with type 1 diabetes (T1D) and ﬁve trials included a total of
3360 patients with type 2 diabetes (T2D); all trials were 26 or 52 weeks in duration. Conﬁrmed
hypoglycaemia was deﬁned as plasma glucose <3.1 mmol/L or severe episodes requiring assis-
tance, and nocturnal hypoglycaemia occurred between 00:01 and 05:59. In all trials, the mean
end-of-trial FPG was lower for IDeg than IGlar, reaching statistical signiﬁcance in three trials.
Similarly, IDeg was associated with a lower rate of nocturnal conﬁrmed hypoglycaemia vs. IGlar,
which was statistically signiﬁcant in three trials, regardless of type of diabetes or background
therapy.
Conclusion: This analysis shows that the lower rate of nocturnal conﬁrmed hypoglycaemia seen
with IDeg relative to IGlar is accompanied by a reduced mean FPG, in particular in patients with
T2D.
ª 2015 Elsevier B.V. All rights reserved.variance; CI, conﬁdence interval; FPG, fasting plasma glucose; IDeg, insulin degludec; IDet, insulin
, last observation carried forward; NPH, neutral protamine Hagedorn; OD, once daily; PPG, post-
f exposure; RR, rate ratio; T1D, type 1 diabetes; T2D, type 2 diabetes.
68665, NCT01059799, NCT01006291, NCT00972283, NCT00982228, NCT01079234.
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Despite the well-established efﬁcacy of insulin, the burden
and fear of hypoglycaemia associated with insulin treat-
ment remains a major barrier to patients achieving the
recommended glycaemic targets [1]. This can result in sub-
optimal glycaemic control and, in patients with type 2
diabetes (T2D), in delayed initiation of insulin [2,3] and
increased risk of developing diabetic complications. The
basal insulin analogues insulin glargine (IGlar) and insulin
detemir (IDet) have helped patients with type 1 diabetes
(T1D) and T2D to achieve improved glycaemic control due
to a reduced risk of hypoglycaemia compared to neutral
protamine Hagedorn (NPH) insulin [4,5]. The pharmaco-
kinetic and pharmacodynamic properties of IGlar and IDet,
however, may be suboptimal due to within-patient vari-
ability, and periods of hyper- and hypoglycaemia [6].
Furthermore, the duration of action may not be sufﬁcient
for once-daily dosing in all patients [7,8].
Insulin degludec (IDeg) is a new basal insulin with a
novel mechanism of protraction, resulting in an ultra-long
duration of action (>42 h) and a half-life ofw25 h [9e11].
Following subcutaneous injection, IDeg hexamers asso-
ciate to form a depot of soluble multihexamers, from
which monomers slowly and continuously enter the cir-
culation [10,12]. This creates a ﬂatter, more stable phar-
macokinetic and pharmacodynamic proﬁle, resulting in
four-times less within-patient variability compared with
IGlar [13]. The BEGIN clinical trial programme investigated
the efﬁcacy and tolerability of IDeg across the spectrum of
diabetes care, including patients with T1D, patients with
insulin-treated T2D and insulin-naïve patients with T2D,
with reduction in HbA1c at end-of-trial as the primary
endpoint. Results of these trials have been published
previously, showing that IDeg is non-inferior to IGlar with
respect to HbA1c lowering, across patient populations
[14e20]. Moreover, in a pre-planned meta-analysis (dis-
cussed with the regulatory authorities) individual patient-
level data from the trials were pooled, so that they could
be analysed as insulin-naïve T2D, all T2D, all T1D, and T1D
and T2D combined. Results showed that the rates of
conﬁrmed and nocturnal conﬁrmed hypoglycaemia were
signiﬁcantly lower in insulin-naïve and all T2D pop-
ulations, and nocturnal conﬁrmed hypoglycaemia was
signiﬁcantly lower in T1D [21]. Despite the treat-to-target
design of the trials, a lower rate of nocturnal conﬁrmed
hypoglycaemia may represent an opportunity for
achieving better fasting plasma glucose (FPG) levels.
HbA1c is a composite endpoint dependent upon both
post-prandial glucose (PPG) and FPG levels. Since the
treat-to-target design of the trials resulted in similar HbA1c
reductions, the question could arise as to whether the
lower rates of hypoglycaemia seen with IDeg were
accompanied by higher FPG and/or PPG values, or whether
aiming for lower PG targets might diminish the hypo-
glycaemia beneﬁt observed with IDeg. We therefore per-
formed this exploratory post hoc meta-analysis of
nocturnal conﬁrmed hypoglycaemia and FPG levels in
patients treated with IDeg or IGlar, in order to address theclinical dilemma of aiming for better glycaemic control vs.
increasing the risk of hypoglycaemia.
Methods
This post hoc meta-analysis included seven phase 3a,
randomised, open-label, parallel, treat-to-target clinical
trials in which once-daily (OD) IDeg was compared with
OD IGlar (two in T1D and ﬁve in T2D) over 26 or 52 weeks.
Data from the ‘forced ﬂexible’ dosing arms in two trials
were not included in this analysis as these extreme dosing
interval regimens do not represent the recommended use
of IDeg in clinical practice and may confound the results
[17,18]. In all trials, insulin doses were titrated to achieve
pre-breakfast self-measured plasma glucose levels of
3.9e4.9 mmol/L (70e90 mg/dL), using the same titration
guideline for both IDeg and IGlar [14e20].
Mean FPG and the estimated treatment difference in
FPG reduction at the end of the titration period, during the
maintenance period and at end-of-trial were analysed.
Similarly, the rate (in episodes per patient year of exposure
[PYE]) and rate ratio of nocturnal conﬁrmed hypo-
glycaemia at the end of the titration period, during the
maintenance period and end-of-trial were analysed. The
titration period was deﬁned as the ﬁrst 15 weeks of each
trial, when active insulin dose titration took place. The
maintenance period was deﬁned as week 16 until the end
of treatment, when stable glycaemic control and insulin
dose had usually been achieved. Results for the titration
and maintenance periods were analysed separately.
Conﬁrmed hypoglycaemia was deﬁned as plasma glucose
<3.1 mmol/L (56 mg/dL) or severe episodes requiring
third-party assistance. Conﬁrmed or severe hypoglycaemic
episodes occurring between 00:01 and 05:59 inclusive
were classiﬁed as nocturnal. The proportion of patients
reaching FPG target and those doing so without nocturnal
conﬁrmed hypoglycaemia were also analysed for the four
basal-oral therapy trials (patients were insulin-naïve in
three out of four trials) [22].
Statistics
Post-baseline missing values were imputed using last
observation carried forward (LOCF). Change in FPG was
analysed using analysis of covariance (ANCOVA) with ﬁxed
factors for treatment, sex, region, and anti-diabetic therapy
at screening, and with age and baseline value as covariates.
In the FPG meta-analyses, the model also included trial as
a ﬁxed factor. Treatment differences were reported with
95% conﬁdence interval (CI), for each trial and for the
following patient populations: all T2D, all T1D and
T1D þ T2D combined. The patient-level meta-analysis of
rate of nocturnal conﬁrmed hypoglycaemia was performed
as described in Ratner et al. [21]. Rates of hypoglycaemia
were analysed using a negative binomial regression model
using a log-link and with trial, treatment, sex, region and
antidiabetic therapy at screening as ﬁxed effects, age as
covariate and logarithm of the exposure time as an offset.
Treatment differences were reported as estimated rate
900 D. Russell-Jones et al.ratios (RRs) of IDeg/IGlar, with 95% CI, for each trial and for
the following patient populations: all T2D, all T1D and T1D
and T2D combined. The composite endpoint of patients
achieving FPG target without nocturnal conﬁrmed hypo-
glycaemia was analysed post hoc using a logistic regression
model with logit link, which included treatment, sex, trial,
antidiabetic treatment at screening, and region as ﬁxed
factors, and age and baseline FPG as covariates. Statistical
signiﬁcance was deﬁned as p < 0.05.
Results
An overview of the patients randomised and the design of
the seven BEGIN phase 3a clinical trials included in this
analysis is presented in Table 1. These trials illustrated that
IDeg is non-inferior to IGlar with respect to HbA1c lowering
[14e20]. Due to the treat-to-target design of the trials, it
was expected that there would be no difference in end-of-
trial HbA1c with IDeg and IGlar. For each of the seven tri-
als,mean FPG levelswere signiﬁcantly or numerically lower
with IDeg than with IGlar at end-of-trial, at the end of the
titration period and during the maintenance period, with
the difference reaching statistical signiﬁcance in three trials
at end-of-trial, four trials at the end of the titration period
and one trial during the maintenance period (Table 2). All
pooled patient populations (all T1D, all T2D, and T1D and
T2D combined) also had lower mean FPG with IDeg
compared with IGlar that reached statistical signiﬁcance
during the three periods, with the exception of the T1D
pooled population during the maintenance period, which
was numerically but not signiﬁcantly lower.
At end-of-trial, treatment with IDeg resulted in rates of
nocturnal conﬁrmed hypoglycaemia that were numerically
or signiﬁcantly lower than those with IGlar, in all trials
(signiﬁcant in three trials). During the titration period,
rates of nocturnal hypoglycaemia with IDeg were similar
to or numerically lower than those with IGlar, and in one
trial (3668) rates were signiﬁcantly lower. During the
maintenance period, rates were numerically or signiﬁ-
cantly lower with IDeg than with IGlar (signiﬁcantly lowerTable 1 Overview of the seven clinical trials included in the meta-analys
Study ID Patients Trial
duration
(weeks)
Randomisation
(IDeg:IGlar)
BEGIN Once Long (3579) T2D
(insulin-naïve)
52 3:1
BEGIN Low Volume (3672) T2D
(insulin-naïve)
26 1:1
BEGIN Once Asia (3586) T2D
(insulin-naïve)
26 2:1
BEGIN Flex (3668) T2D 26 1:1
BEGIN Basal-bolus
Type 2 (3582)
T2D 52 3:1
BEGIN Basal-bolus
Type 1 (3583)
T1D 52 3:1
BEGIN Flex T1 (3770) T1D 26 1:1
IDeg, insulin degludec; IGlar, insulin glargine; SD, standard deviation; T1Din three trials) (Table 3). The end-of-trial rates of nocturnal
conﬁrmed hypoglycaemia were signiﬁcantly lower for the
pooled T2D and pooled T1D þ T2D, and numerically lower
for the pooled T1D population. They were signiﬁcantly
lower for all pooled populations during the maintenance
period and for the pooled T1D þ T2D group during the
titration period.
A separate analysis of the four basal insulin-oral ther-
apy trials in patients with T2D showed that more patients
achieved the FPG target of <5 mmol/L (90 mg/dL) with
IDeg (40.9%) vs. IGlar (29.4%). Additionally, the probability
of patients reaching the FPG target without experiencing
nocturnal conﬁrmed hypoglycaemia was signiﬁcantly
higher with IDeg (34.9% of patients) compared with IGlar
(23.8% of patients): estimated odds ratio IDeg/IGlar: 1.82
[1.49; 2.22]95% CI, corresponding to an 82% increase in the
odds (Fig. 1) [22].
Discussion
This analysis shows that the lower rate of nocturnal
conﬁrmed hypoglycaemia seen in patients treated with
IDeg compared with IGlar was accompanied by greater
reductions in FPG across the IDeg phase 3a clinical trials, as
summarised in Fig. 2. The reduction in FPG with IDeg was
statistically signiﬁcantly or numerically lower compared
with IGlar in all the individual trials, over different time-
scales (entire trial, titration period, maintenance period),
and in the pooled populations (pooled T2D, pooled T1D,
and pooled T1D þ T2D). Therefore, it is conceivable that a
lower risk of nocturnal hypoglycaemia may provide an
opportunity to achieve a more physiological FPG level. In
keeping with this hypothesis, the chance of achieving FPG
target for patients with T2D on basal-oral therapy without
nocturnal conﬁrmed hypoglycaemia has been found to be
signiﬁcantly higher with IDeg vs. IGlar [22]. This is spe-
ciﬁcally relevant for the large number of patients with T2D
initiating insulin therapy in primary care in order to
intensify their previous treatment and achieve better gly-
caemic control.is.
Number of patients
randomised
Age (years,
mean  SD)
Gender
(F/M, %)
Baseline FPG
(mmol/L, mean  SD)
IDeg IGlar IDeg IGlar
773 257 59.1  9.8 38/62 9.6  2.6 9.7  2.6
230 230 57.5  9.2 47/53 9.6  2.9 9.7  2.6
289 146 58.6  9.9 46/54 9.6  2.1 9.7  1.9
226 229 56.4  9.6 50/50 8.8  2.8 9.0  2.8
755 251 58.9  9.3 46/54 9.2  3.0 9.2  3.2
472 157 43.0  13.6 41/59 9.1  4.0 9.7  4.4
165 164 43.7  13.1 45/55 10.0  4.0 9.7  4.2
, type 1 diabetes; T2D type 2 diabetes.
Table 2 Mean fasting plasma glucose at the end of the trials and during the titration and maintenance periods.
Study ID Patients End of trial Titration period Maintenance period
FPG (mmol/L,
mean  SEM)
Estimated treatment
difference, IDeg  IGlar
(mmol/L [95% CI])
FPG (mmol/L, mean  SEM) Estimated treatment
difference, IDeg  IGlar
(mmol/L [95% CI])
FPG (mmol/L,
mean  SEM)
Estimated treatment
difference, IDeg  IGlar
(mmol/L [95% CI])
IDeg IGlar IDeg IGlar IDeg IGlar
BEGIN Once
Long (3579)
T2D
(insulin-naïve)
n Z 1030
5.9  0.08
(n Z 769)
6.4  0.14
(n Z 257)
0.43 [0.74; 0.13]* 6.2  0.07
(n Z 773)
6.6  0.13
(n Z 257)
0.40 [0.67; 0.13]* 5.6  0.07
(n Z 685)
6.1  0.14
(n Z 226)
0.26 [0.54; 0.02]
BEGIN Low
Volume (3672)
T2D
(insulin-naïve)
n Z 460
5.9  0.20
(n Z 228)
6.3  0.20
(n Z 229)
0.42 [0.78; 0.06]* 6.0  0.13
(n Z 228)
6.1  0.12
(n Z 229)
0.15 [0.49; 0.20] 5.7  0.12
(n Z 206)
6.1  0.14
(n Z 210)
0.38 [0.72; 0.04]*
BEGIN Once
Asia (3586)
T2D
(insulin-naïve)
n Z 435
5.5  0.09
(n Z 289)
5.7  0.12
(n Z 146)
0.09 [0.41; 0.23] 5.5  0.09
(n Z 289)
5.7  0.13
(n Z 146)
0.21 [0.51; 0.09] 5.4  0.09
(n Z 261)
5.6  0.13
(n Z 139)
0.04 [0.33; 0.25]
BEGIN Flex
(3668)
T2D
n Z 455
5.8  0.16
(n Z 228)
6.2  0.16
(n Z 228)
0.38 [0.79; 0.04] 6.0  0.14
(n Z 228)
6.5  0.16
(n Z 230)
0.45 [0.84; 0.06]* 5.6  0.14
(n Z 206)
5.9  0.13
(n Z 208)
0.10 [0.42; 0.23]
BEGIN Basal-bolus
Type 2 (3582)
T2D
n Z 1006
6.8  0.09
(n Z 743)
7.1  0.17
(n Z 248)
0.29 [0.65; 0.06] 6.9  0.09
(n Z 744)
7.3  0.18
(n Z 248)
0.34 [0.70; 0.02] 6.7  0.09
(n Z 677)
7.0  0.17
(n Z 233)
0.19 [0.54; 0.15]
BEGIN Basal-bolus
Type 1 (3583)
T1D
n Z 629
7.8  0.17
(n Z 472)
8.3  0.34
(n Z 155)
0.33 [1.03; 0.36] 7.6  0.16
(n Z 472)
8.7  0.29
(n Z 157)
1.01 [1.63; 0.39]* 7.8  0.18
(n Z 448)
8.3  0.34
(n Z 148)
0.30 [1.02; 0.41]
BEGIN Flex T1
(3770)
T1D
n Z 329
7.4  0.27
(n Z 165)
8.4  0.28
(n Z 163)
0.97 [1.74; 0.20]* 7.2  0.30
(n Z 165)
8.4  0.30
(n Z 164)
1.17 [2.01; 0.33]* 7.3  0.26
(n Z 148)
8.3  0.29
(n Z 155)
0.72 [1.48; 0.03]
Overall T2D pooled e e 0.33 [0.49; 0.17]* e e 0.32 [0.48; 0.17]* e e 0.21 [0.36; 0.06]*
Overall T1D pooled e e 0.61 [1.13; 0.10]* e e 1.10 [1.60; 0.60]* e e 0.48 [1.00; 0.05]
Overall T1D þ T2D
pooled
e e 0.40 [0.57; 0.23]* e e 0.50 [0.66; 0.34]* e e 0.27 [0.43; 0.10]*
*p < 0.05. Missing values are imputed using last observation carried forward (LOCF). IDeg, insulin degludec; IGlar, insulin glargine; SEM, standard error of the mean; T1D, type 1 diabetes; T2D type 2
diabetes.
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Table 3 Nocturnal conﬁrmed hypoglycaemia risk at the end of trial and during the titration and maintenance periods.
Study ID Patients End of trial Titration period Maintenance period
Exposure
weeks
Episodes
(% patients)
Rate per PYE Rate ratio,
IDeg vs. IGlar
[95% CI]
Exposure
weeks
Episodes
(% patients)
Rate per PYE Rate ratio,
IDeg vs.
IGlar [95% CI]
Exposure
weeks
Episodes
(% patients)
Rate per PYE Rate ratio,
IDeg vs.
IGlar
[95% CI]
IDeg IGlar IDeg IGlar IDeg IGlar IDeg IGlar IDeg IGlar IDeg IGlar
BEGIN Once
Long (3579)
T2D 52 169
(13.8)
84
(15.2)
0.25 0.39 0.64
[0.42; 0.98]*
16 362
(24.7)
136
(27.9)
0.23 0.16 1.26
[0.57; 2.78]
36 118
(12.3)
72
(14.2)
0.27 0.50 0.51
[0.32; 0.81]*
BEGIN Low
Volume
(3672)
T2D 26 19
(6.1)
30
(8.8)
0.18 0.28 0.64
[0.30; 1.37]
16 11
(4.4)
12
(3.9)
0.17 0.18 0.97
[0.37; 2.50]
10 8
(2.9)
18
(7.1)
0.21 0.45 0.45
[0.17; 1.19]
BEGIN Once
Asia (3586)
T2D 26 104
(20.4)
87
(24.0)
0.78 1.24 0.62
[0.38; 1.04]
16 71
(15.5)
54
(19.2)
0.85 1.23 0.68
[0.39; 1.19]
10 33
(10.7)
33
(12.2)
0.66 1.25 0.52
[0.27; 1.01]
BEGIN Flex
(3668)
T2D 26 67
(13.5)
58
(10.6)
0.56 0.75 0.64
[0.37; 1.11]
16 24
(6.6)
44
(14.8)
0.37 0.66 0.51
[0.27; 0.95]*
10 34
(7.8)
35
(11.5)
0.88 0.89 0.82
[0.39; 1.74]
BEGIN
Basal-bolus
Type 2
(3582)
T2D 52 930
(39.6)
422
(47.4)
1.39 1.84 0.75
[0.58; 0.99]*
16 362
(24.7)
136
(27.9)
1.63 1.81 0.86
[0.62; 1.18]
36 568
(29.7)
286
(37.0)
1.27 1.86 0.72
[0.51; 1.00]*
BEGIN
Basal-bolus
Type 1
(3583)
T1D 52 1905
(72.2)
845
(74.0)
4.41 5.86 0.75
[0.59; 0.96]*
16 769
(54.4)
333
(59.1)
5.43 7.20 0.78
[0.60; 1.02]
36 1136
(60.3)
512
(64.2)
3.91 5.22 0.73
[0.56; 0.96]*
BEGIN Flex
T1 (3770)
T1D 26 453
(67.7)
732
(73.3)
9.61 9.96 0.99
[0.72; 1.34]
16 517
(68.5)
497
(65.2)
10.69 10.23 1.05
[0.77; 1.44]
10 215
(48.6)
285
(49.7)
7.72 9.51 0.83
[0.55; 1.25]
Overall T2D pooled 0.68
[0.57; 0.82]*
0.81
[0.64; 1.02]
0.62
[0.49; 0.78]*
Overall T1D pooled 0.83
[0.69; 1.00]
0.88
[0.72; 1.08]
0.75
[0.60; 0.94]*
Overall T1D þ T2D
pooled
0.75
[0.65; 0.85]*
0.86
[0.74; 1.00]*
0.68
[0.58; 0.80]*
*Signiﬁcantly lower risk based on the 95% conﬁdence intervals.
IDeg, insulin degludec; IGlar, insulin glargine; PYE, patient years of exposure; T1D, type 1 diabetes; T2D type 2 diabetes. The number of nocturnal conﬁrmed hypoglycaemic episodes within trial are
analysed using a Negative Binomial Regression Model using a log-link and with trial, treatment, sex, region and anti-diabetic therapy at screening as ﬁxed effects, age as covariate and logarithm the
exposure time as offset.
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Figure 1 Patients on basal-oral therapy achieving FPG target without
nocturnal conﬁrmed hypoglycaemia [22]. a. Percent of patients; b.
Estimated odds ratio.
Figure 2 Change from baseline in FPG and rate of nocturnal conﬁrmed
hypoglycaemia at the end of the trials.
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that the rate ratio for overall conﬁrmed hypoglycaemia was
lower with IDeg vs. IGlar [21]. However, as the difference
was not signiﬁcant in all the individual trials, one could
argue that the rate of nocturnal conﬁrmed hypoglycaemia
was offset by increased day-time hypoglycaemia. This was
directly investigated in two studies showing no signiﬁcant
difference in the rate of diurnal conﬁrmed hypoglycaemia
in patients with T1D or T2D [14,16]. Further meta-analyses
conﬁrmed that the reduction in nocturnal conﬁrmed
hypoglycaemia was not accompanied by increased rates of
daytime conﬁrmed hypoglycaemia in pooled T1D, pooled
T2D and pooled insulin-naïve T2D [23]. The trial protocol
for insulin-experienced patients required that those who
were switching from twice-daily to once-daily insulin
dosing administer their total pre-trial basal insulin dose in
the IDeg arm, but reduce the dose by 20e30% in the IGlar
arm (as per the prescribing information). This could have
biased the hypoglycaemia rates in favour of IGlar during the
ﬁrstweeks of the trials as the dosewas lower [16]. However,
the IGlar dose subsequently increased as patients titrated to
target and end-of-trial doses for pooled T1D patients were
higher with IGlar compared with IDeg [23].
Despite clinical guidelines recommending the attain-
ment of glycaemic targets of HbA1c < 7.0% and
FPG < 7.2 mmol/L [24] many patients are unable to reach
these targets. This may in part be due to the fear of
hypoglycaemia. Traditionally, it has been thought that
although lower FPG results in improved glycaemic control,
this could be achieved at the expense of an unacceptably
high risk of nocturnal conﬁrmed hypoglycaemia [1,25]. The
BEGIN trial programme, which had an ambitious treat-
ment target (FPG 3.9e4.9 mmol/L), suggests that the ﬂat
and stable proﬁle of IDeg, coupled with low within patient
variability, may offer a better opportunity to achieve such a
goal [9,13]. This could encourage healthcare professionals
to attempt to achieve normoglycaemia in their patients
with T1D and T2D, with a reduced risk of nocturnal
hypoglycaemia.
The lack of a signiﬁcant difference in HbA1c may appear
at variance with attainment of a lower FPG. However,
because of the treat-to-target nature of the study and the
primary endpoint of non-inferiority, a difference in HbA1c
was not expected. It is for this very reason that demon-
strating a moderate but signiﬁcant reduction in FPG while
using a treat-to-target treatment strategy becomes of
particular interest. Moreover, physicians should be aware
that the beneﬁt of a greater FPG reduction could be offset
by changes in diurnal/post-prandial plasma glucose pro-
ﬁles, which are largely dependent on oral agents or pre-
prandial short-acting insulin administration.
Finally, these data should be placed in the context of
clinical practice, where additional barriers (such as fear of
injections, difﬁculty in adhering to strict treatment regi-
mens) hamper insulin therapy optimisation [2,26]. It will
be of interest to observe to what extent the potential of
IDeg observed in randomised, controlled clinical trials will
translate into clinical practice. This is of particular interest
because a limitation of this study is the rates of
904 D. Russell-Jones et al.hypoglycaemia recorded in the trials appear to be lower
than those seen in clinical practice, as patients with
recurrent severe hypoglycaemia were excluded.
Conversely, the reporting of hypoglycaemic events is likely
to be more accurate in controlled clinical trials than clin-
ical practice where hypoglycaemia is less commonly re-
ported and discussed with the doctor [27]. It is
acknowledged that some hypoglycaemic episodes are
asymptomatic, as continuous glucose monitoring was not
conducted during this trial programme asymptomatic
episodes of nocturnal hypoglycaemia would not be iden-
tiﬁed. An additional limitation is the open-label nature of
all the trials (due to the use of different injection devices),
however, the inclusion of only hypoglycaemia that was
accompanied by a PG reading or requiring assistance
should make any bias negligible.
The reduced risk of nocturnal hypoglycaemia and better
FPG observed with IDeg may result in additional positive
features of this long-acting insulin analogue, including
greater ﬂexibility as supported by the ‘forced ﬂexible’
dosing regimen showing that glycaemic control and safety
were not compromised when IDeg was dosed at extreme
intervals [17,18]. The ability to dose IDeg with some ﬂexi-
bility has been reﬂected in the prescribing information
[28] and may enable patients some respite from the strict
regimens requiring dosing at the same time each day.
Furthermore the results from a previous meta-analysis of
data from patients on basal-oral therapy showed an
improvement in health-related quality of life was seen in
patients taking IDeg compared with IGlar, assessed using
the Short-form 36 v2 questionnaire and EQ-5D health
utility scale [29,30]. It has also been shown that frequency
of hypoglycaemia and perceived poor metabolic control
are negatively associated with quality of life [31].
In conclusion, this exploratory post hoc meta-analysis
shows that the lower rate of nocturnal conﬁrmed hypo-
glycaemia seen with IDeg relative to IGlar is accompanied
by reduced FPG, in particular in patients with T2D. This
analysis suggests that IDeg may help patients to reach FPG
target with a reduced risk of nocturnal conﬁrmed
hypoglycaemia.
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